By Josh Beckerman

Lixte Biotechnology Holdings continued their upward trajectory Thursday as the pharmaceutical company said it believes it has regained compliance with Nasdaq's stockholders' equity requirement after a private placement.

Shares rose 40%, to $2.83, in the shortened regular session Thursday and were recently at $2.65 after hours. Trading volume was 63.97 million shares in the regular session, compared with a 65-day average of 818,062.

The stock closed at 71 cents on June 27, with closing prices of 91 cents and $1.18 for the next two sessions.

Lixte said after the bell Tuesday that it agreed to sell $5 million of securities, including common stock or pre-funded warrants, Series B convertible preferred stock and common warrants. On Wednesday, shares surged 71%.

Lixte previously disclosed a Nasdaq non-compliance with the $2.5 minimum stockholders' equity requirement. In a Thursday securities filing, Lixte said it believes it has stockholders' equity in excess of $2.5 million and is awaiting a compliance determination from Nasdaq.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 03, 2025 14:53 ET (18:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.